Shell Asset Management Co. purchased a new stake in shares of HilleVax, Inc. (NASDAQ:HLVX – Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 2,441 shares of the company’s stock, valued at approximately $41,000.
A number of other institutional investors have also recently added to or reduced their stakes in the company. New York State Common Retirement Fund grew its position in HilleVax by 17.5% during the fourth quarter. New York State Common Retirement Fund now owns 11,085 shares of the company’s stock valued at $185,000 after acquiring an additional 1,652 shares during the period. Bank of New York Mellon Corp boosted its position in shares of HilleVax by 31.6% in the third quarter. Bank of New York Mellon Corp now owns 41,510 shares of the company’s stock worth $710,000 after buying an additional 9,966 shares during the period. BNP Paribas Arbitrage SNC purchased a new stake in shares of HilleVax in the third quarter worth about $151,000. State Street Corp boosted its position in shares of HilleVax by 33.5% in the third quarter. State Street Corp now owns 219,137 shares of the company’s stock worth $3,745,000 after buying an additional 54,965 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of HilleVax by 3.1% in the third quarter. Vanguard Group Inc. now owns 629,754 shares of the company’s stock worth $10,763,000 after buying an additional 18,947 shares during the period. Hedge funds and other institutional investors own 99.11% of the company’s stock.
HilleVax Price Performance
Shares of NASDAQ HLVX opened at $14.29 on Friday. HilleVax, Inc. has a 1-year low of $7.90 and a 1-year high of $24.42. The business has a 50-day moving average of $14.78 and a 200-day moving average of $16.32. The company has a debt-to-equity ratio of 0.06, a current ratio of 22.28 and a quick ratio of 22.28. The company has a market capitalization of $560.17 million and a price-to-earnings ratio of -1.09.
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
- Get a free copy of the StockNews.com research report on HilleVax (HLVX)
- MarketBeat Week in Review – 5/8 – 5/12
- An Updraft Is Brewing For DraftKings
- PepsiCo Hits “Sweet Spot” For APAC Growth, Macros Agree
- High-Risk Mullen Automotive Continues To Build Momentum
- 3 Recession-Proof Stocks With Nice Dividends
Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.